

**Amendments to the Claims:**

Please cancel Claims 1 through 14, and enter instead the new claims below, numbering 15 through 33. With this amendment, Claims 15 through 33 will be pending in the application. This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled)

14. (New) The use of a compound that is effective as selective opiate receptor modulator for the manufacture of a pharmaceutical for the diagnosis, prophylaxis and/or the treatment of neuropathy, the clinical pictures and symptoms associated therewith, and related disorders.

15. (New) The use according to claim 14, characterized in that said receptor modulator is a receptor agonist.

16. (New) The use according to claim 14, characterized in that said receptor modulator is peripherally selective to the receptor.

17. (New) The use according to claim 14, characterized in that said opiate receptor is a kappa-opiate receptor.

18. (New) The use according to claim 14, characterized in that said receptor modulator is a receptor agonist, that said receptor modulator is peripherally selective to the receptor and that said opiate receptor is a kappa-opiate receptor

19. (New) The use according to claim 14, characterized in that the compound is selected from group consisting of Alvimopan, Loperamide, Asimadoline, Fedotozine, Pentazocine, U62066E, ICI204448, U-50488H, ADL 10-0101, ADL 10-0116 and ADL 1-0398.

20. (New) The use according to claim 14, characterized in that the compound that is effective as selective opiate receptor modulator is N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide, and/or a pharmaceutically acceptable derivative, solvate, salt or stereoisomer thereof, including mixtures thereof in all ratios.

21. (New) The use according to claim 14, characterized in that the related disorders are selected from the group consisting of post-herpetic neuralgia, vulvodynia, lupus erythematosus and chemotherapy induced neuropathy.

22. (New) The use according to claim 19, characterized in that the related disorders are selected from the group consisting of post-herpetic neuralgia, vulvodynia, lupus

erythematosis and chemotherapy induced neuropathy.

23. (New) The use according to claim 14, characterized in that the compound that is effective as selective opiate receptor modulator is N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide, hydrochloride, and that the disorders are selected from the prophylaxis and the treatment of neuropathy.

24. (New) A pharmaceutical composition, characterized in that it comprises a pharmaceutically effective amount of one or more compounds effective as selective opiate receptor modulators as defined in claim 14.

25. (New) A pharmaceutical composition, characterized in that it comprises a pharmaceutically effective amount of one or more compounds effective as selective opiate receptor modulators as defined in claim 19.

26. (New) A pharmaceutical composition, characterized in that it comprises a pharmaceutically effective amount of one or more compounds effective as selective opiate receptor modulators as defined in claim 14, and in that it contains one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutically active ingredients other than the compounds according to claim 14.

27. (New) A pharmaceutical composition, comprising a pharmaceutically effective amount of one or more compounds effective as selective opiate receptor modulators as defined in claim 14, further comprising one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutically active ingredients other than the compounds according to claim 14, wherein the pharmaceutically active ingredients other than the compounds according to claim 14 are selected from anti-diabetics and pharmaceutically active ingredients other than the compounds according to claim 14 that are useful for the diagnosis, prophylaxis and/or the treatment of neuropathy, the clinical pictures and symptoms associated therewith, and related

disorders.

28. (New) A pharmaceutical composition, comprising a pharmaceutically effective amount of one or more compounds according to claim 19, further comprising one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutically active ingredients other than the compounds according to claim 19, wherein the pharmaceutically active ingredients other than the compounds according to claim 19 are selected from anti-diabetics and pharmaceutically active ingredients useful for the diagnosis, prophylaxis and/or the treatment of neuropathy, the clinical pictures and symptoms associated therewith, and related disorders, other than the compounds according to claim 19.

29. (New) A method for the manufacture of a pharmaceutical composition according to 26, characterized in that the one or more compounds effective as selective opiate receptor modulator and optionally the one or more additional compounds are mixed together and converted into a pharmaceutical composition suitable for administration.

30. (New) A method for the diagnosis, prophylaxis and/or the treatment of neuropathy, the clinical pictures and symptoms associated therewith, and related disorders, comprising administering to the patient in need thereof a pharmaceutically effective amount of at least one compound that is effective as selective opiate receptor modulator.

31. (New) A method for the diagnosis, prophylaxis and/or the treatment of neuropathy, the clinical pictures and symptoms associated therewith, and related disorders, comprising administering to the patient in need thereof a pharmaceutically effective amount of at least one compound according to claim 19.

32. (New) Kit consisting of separate packs of  
a) a pharmaceutically effective amount of one or more selective opiate receptor modulators as defined in claim 14, and

b) a pharmaceutically effective amount of one or more compounds, selected from pharmaceutically active ingredients other than the compounds according to claim 14.

33. (New) Kit consisting of separate packs of

a) a pharmaceutically effective amount of one or more selective opiate receptor modulators as defined in claim 19, and

b) a pharmaceutically effective amount of one or more compounds, selected from pharmaceutically active ingredients other than the compounds according to claim 19.